Beta-blockers are a valuable class of drugs for optimizing antihypertensive treatment, particularly in high-risk patients with specific comorbidities.
No takes yet. Share an insight, caveat, or question.
Supports beta-blocker optimization in comorbid hypertension; leaves open need for updated RCTs.
Jan Basile (2003) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: